Abstract
Objective To explore how different diets may affect human brain development and if genetic and environmental factors play a part.
Design Cohort study.
Setting UK Biobank data were collected from 22 centres across the UK.
Participants Only white British individuals free of Alzheimer’s or dementia diseases were included in the study, where 336517 participants had quality-controlled genetic data, and 18879 participants had qualified brain MRI data.
Main outcome measures Grey matter volume, intake of cereal and coffee, body mass index and blood cholesterol level.
Results We investigated diet effects in the UK Biobank data and discovered anti-correlated brain-wide grey matter volume (GMV)-association patterns between coffee and cereal intake, coincidence with their anti-correlated genetic constructs. These genetic factors may further affect people’s lifestyle habits and body/blood fat levels through the mediation of cereal/coffee intake, and the brain-wide expression pattern of gene CPLX3, a dedicated marker of subplate neurons that regulate cortical development and plasticity, may underlie the shared GMV-association patterns among the coffee/cereal intake and cognitive functions.
Conclusions Our findings revealed that high-cereal and low-coffee diets shared similar brain and genetic constructs, leading to long-term beneficial associations regarding cognitive, BMI and other metabolic measures. This study has important implications for public health, especially during the pandemic, given the poorer outcomes of COVID-19 patients with greater BMIs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work received support from the following sources: the National Key Research and Development Program of China (2018YFC1312900 and 2019YFA0709502), the National Natural Science Foundation of China (91630314 and 81801773), the 111 Project (B18015), The Key Project of Shanghai Science &Technology Innovation Plan(16JC1420402), the Shanghai Municipal Science and Technology Major Project (2018SHZDZX01) and Zhangjiang Lab. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK Biobank study received ethical approval from the NHS National Research Ethics Service North West (reference number: 16/NW/0274). Data access permission was granted under UKB application 19542.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All UK Biobank data used in this work were obtained under Data Access Application 19542 and are available to eligible researchers through the UK Biobank (www.biobank.ac.uk). Gene expression data from the Allen Institute for Brain Science are freely available at https://human.brain-map.org/static/download. Custom code that supports the findings of this study is available from the corresponding author upon request.
